☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Sibutramine licence suspended

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the suspension of the licence for sibutramine (Reductil®), a weight loss medication recommended as an adjunctive therapy within a weight management programme.

Additional documentation (Press release and Q&A) is available on the European Medicines Agency (EMA) website. Recent study results have linked this medication with an increased risk of cardiovascular events and authorities now consider that the risks of treatment outweigh the benefits.

Action: Doctors are advised to no longer prescribe this medication. Patients are advised to consult their doctor to discuss alternative treatments and may stop taking treatment prior to this discussion if they wish.

Share 'Sibutramine licence suspended' on Email Share 'Sibutramine licence suspended' on Delicious Share 'Sibutramine licence suspended' on Digg Share 'Sibutramine licence suspended' on Facebook Share 'Sibutramine licence suspended' on reddit Share 'Sibutramine licence suspended' on Twitter


One Comments to “Sibutramine licence suspended”

  1. [...] The New England Journal of Medicine has published the results of the SCOUT or Sibutramine Cardiovascular OUTcomes study. This study aimed to assess the effect of sibutramine (Reductil®) in individuals considered to be at high risk of a cardiovascular event. The results of this study led to the withdrawal of the drug in Europe in January 2010. [...]

    Pingback by Prescribing Advice For GPs » SCOUT Is Out — September 14, 2010 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.